×
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.96 (+1.71%)
AAPL   141.56 (+1.89%)
MSFT   262.85 (+1.26%)
META   168.19 (+5.10%)
GOOGL   2,265.26 (+4.16%)
AMZN   113.50 (+3.60%)
TSLA   699.20 (+2.55%)
NVDA   149.64 (+3.04%)
NIO   22.18 (+3.84%)
BABA   120.13 (+3.56%)
AMD   75.20 (+2.08%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.17 (-0.66%)
GE   62.03 (-2.38%)
F   11.20 (-1.06%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.40 (+4.20%)
NFLX   185.88 (+3.30%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.96 (+1.71%)
AAPL   141.56 (+1.89%)
MSFT   262.85 (+1.26%)
META   168.19 (+5.10%)
GOOGL   2,265.26 (+4.16%)
AMZN   113.50 (+3.60%)
TSLA   699.20 (+2.55%)
NVDA   149.64 (+3.04%)
NIO   22.18 (+3.84%)
BABA   120.13 (+3.56%)
AMD   75.20 (+2.08%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.17 (-0.66%)
GE   62.03 (-2.38%)
F   11.20 (-1.06%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.40 (+4.20%)
NFLX   185.88 (+3.30%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.96 (+1.71%)
AAPL   141.56 (+1.89%)
MSFT   262.85 (+1.26%)
META   168.19 (+5.10%)
GOOGL   2,265.26 (+4.16%)
AMZN   113.50 (+3.60%)
TSLA   699.20 (+2.55%)
NVDA   149.64 (+3.04%)
NIO   22.18 (+3.84%)
BABA   120.13 (+3.56%)
AMD   75.20 (+2.08%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.17 (-0.66%)
GE   62.03 (-2.38%)
F   11.20 (-1.06%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.40 (+4.20%)
NFLX   185.88 (+3.30%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.96 (+1.71%)
AAPL   141.56 (+1.89%)
MSFT   262.85 (+1.26%)
META   168.19 (+5.10%)
GOOGL   2,265.26 (+4.16%)
AMZN   113.50 (+3.60%)
TSLA   699.20 (+2.55%)
NVDA   149.64 (+3.04%)
NIO   22.18 (+3.84%)
BABA   120.13 (+3.56%)
AMD   75.20 (+2.08%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.17 (-0.66%)
GE   62.03 (-2.38%)
F   11.20 (-1.06%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.40 (+4.20%)
NFLX   185.88 (+3.30%)
NASDAQ:KRTX

Karuna Therapeutics Earnings Date, Estimates & Call Transcripts (2022)

$132.00
+5.90 (+4.68%)
(As of 07/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$123.70
$134.00
50-Day Range
$93.97
$126.51
52-Week Range
$92.26
$161.98
Volume
607,743 shs
Average Volume
247,792 shs
Market Capitalization
$3.94 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$177.70

Earnings Summary

Upcoming
Earnings Date
Aug. 4Estimated
Actual EPS
(May. 5)
-$1.95 Beat By $0.15
Consensus EPS
(May. 5)
-$2.10
Skip Charts & View Estimated and Actual Earnings Data

KRTX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

KRTX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Karuna Therapeutics Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20223($2.12)($1.64)($1.91)
Q2 20224($2.06)($1.64)($1.89)
Q3 20223($1.97)($1.53)($1.77)
Q4 20223($1.75)($1.55)($1.68)
FY 202213($7.90)($6.36)($7.25)
Q1 20232($1.78)($1.73)($1.76)
Q2 20232($1.84)($1.75)($1.80)
Q3 20232($1.84)($1.73)($1.79)
Q4 20232($1.94)($1.83)($1.89)
FY 20238($7.40)($7.04)($7.22)

KRTX Earnings Date and Information

Karuna Therapeutics last issued its earnings results on May 5th, 2022. The reported ($1.95) earnings per share for the quarter, beating analysts' consensus estimates of ($2.10) by $0.15. Karuna Therapeutics has generated ($5.78) earnings per share over the last year (($5.78) diluted earnings per share). Earnings for Karuna Therapeutics are expected to decrease in the coming year, from ($7.76) to ($7.78) per share. Karuna Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 4th, 2022 based off prior year's report dates.

Karuna Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/4/2022
(Estimated)
        
5/5/20223/31/2022($2.10)($1.95)+$0.15
2/24/2022Q4 2021($1.52)($0.94)+$0.58($0.94)$5.38 million$36.96 million    
11/4/20219/30/2021($1.47)($1.72)($0.25)($1.72)
8/5/20216/30/2021($1.34)($1.17)+$0.17($1.17)
5/6/20213/31/2021($1.14)($1.10)+$0.04($1.10)  
2/25/202112/31/2020($0.89)($0.89)($0.89)
11/5/20209/30/2020($0.82)($0.71)+$0.11($0.71)  
8/5/20206/30/2020($0.45)($0.65)($0.20)($0.65)
5/7/20203/31/2020($0.38)($0.33)+$0.05($0.33)
3/24/202012/31/2019($0.48)($0.32)+$0.16($0.32)
11/7/2019Q3($0.4550)($0.39)+$0.0650($0.39)
8/8/2019Q2 2019($1.19)($146.02)($144.83)($146.02)












Karuna Therapeutics Earnings - Frequently Asked Questions

When is Karuna Therapeutics's earnings date?

Karuna Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 4th, 2022 based off last year's report dates. Learn more on KRTX's earnings history.

Did Karuna Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Karuna Therapeutics (NASDAQ:KRTX) reported ($1.95) earnings per share (EPS) to beat the analysts' consensus estimate of ($2.10) by $0.15. Learn more on analysts' earnings estimate vs. KRTX's actual earnings.

How much revenue does Karuna Therapeutics generate each year?

Karuna Therapeutics (NASDAQ:KRTX) has a recorded annual revenue of $36.96 million.

How much profit does Karuna Therapeutics generate each year?

Karuna Therapeutics (NASDAQ:KRTX) has a recorded net income of -$143.80 million. KRTX has generated -$5.78 earnings per share over the last four quarters.

What is Karuna Therapeutics's EPS forecast for next year?

Karuna Therapeutics's earnings are expected to decrease from ($7.76) per share to ($7.78) per share in the next year.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NASDAQ:KRTX) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.